董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joshua N. Silverman | 男 | Director | 55 | 5.78万美元 | 未持股 | 2025-12-15 |
| Charles Larsen | 男 | Chairperson and Director | 73 | 12.78万美元 | 26.29 | 2025-12-15 |
| Edward Uzialko | 男 | Director | 74 | 6.97万美元 | 125.20 | 2025-12-15 |
| Kathy Lee Sepsick | 女 | Founder, President, CEO and Director | 57 | 114.11万美元 | 181.39 | 2025-12-15 |
| Alistair Milnes | 男 | Director | 51 | 7.97万美元 | 3.46 | 2025-12-15 |
| Joshua Silverman | 男 | Director | 55 | 未披露 | 未持股 | 2025-12-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathy Lee Sepsick | 女 | Founder, President, CEO and Director | 57 | 114.11万美元 | 181.39 | 2025-12-15 |
| Christine Thomas | 女 | Chief Regulatory and Clinical Officer | 52 | 未披露 | 未持股 | 2025-12-15 |
| Dov Elefant | 男 | Chief Financial Officer | 57 | 74.33万美元 | 76.95 | 2025-12-15 |
董事简历
中英对照 | 中文 | 英文- Joshua N. Silverman
-
Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992. - Joshua N. Silverman，自2020年5月28日起担任Stablex Technologies，Inc.董事，目前担任Stablex Technologies，Inc.执行董事长兼首席执行官。在2023年12月13日被任命担任这些职位之前，Silverman先生曾担任董事会主席。在合并之前，Silverman先生自2018年合并（定义见下文）以来一直担任DropCar董事会成员。Silverman先生目前担任Parkfield Funding LLC的管理成员。Silverman先生是投资咨询公司Iroquois Capital Management，LLC（“Iroquois”）的联合创始人，之前是其负责人和管理合伙人。从2003年成立到2016年7月，Silverman先生担任Iroquois的联席首席投资官。在Iroquois任职期间，他设计并执行了复杂的交易，构建和谈判对公共和私营公司的投资，并经常被这类公司要求解决与公司结构、现金流和管理相关的低效率问题。2000年至2003年，Silverman先生担任商业银行Vertical Ventures，LLC的联席首席投资官。在组建Iroquois之前，Silverman先生是专门从事并购的精品咨询公司Joele Frank的董事。此前，Silverman曾担任美国总统助理新闻秘书。Silverman先生目前担任MYMD Pharmaceuticals，Inc.（NASDAQ：MYMD）、Pharmacyte，Inc.（NASDAQ：PMCB）、Synaptogenix, Inc.TERM3（NASDAQ：SNPX）和Petros Pharmaceutical，Inc.（NASDAQ：PTPI）的董事，这些公司均为上市公司。他此前于2014年7月至2016年8月担任国家控股公司董事，并于2016年8月至2018年10月担任Marker Therapeutics公司董事。Silverman先生于1992年获得了Lehigh大学的学士学位。
- Joshua N. Silverman has served as a director of the Company since August 2022 and as Pharmacyte Biotech, Inc.'s Chief Executive Officer, President and Chairman of the Board since October 2022. Mr. Silverman has served as the managing member of Parkfield Funding LLC since August 2016. Mr. Silverman co founded Iroquois Capital Management, LLC ("Iroquois"), an investment advisory firm, in 2003 and served as its principal, managing partner and co chief investment officer until July 2016. While at Iroquois, he designed and executed complex transactions, structuring and negotiating investments in both public and private companies and has often been called upon by the companies solve inefficiencies as they relate to corporate structure, cash flow, and management. From 2000 to 2003, Mr. Silverman served as co chief investment officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr. Silverman was a director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr. Silverman served as assistant press secretary to the president of the U.S. Mr. Silverman currently serves as an Executive Chairman of Fabric AI, Inc., (Nasdaq: FABC), Q/C Technologies, Inc. (Nasdaq: QCLS), TAO Synergies Inc. (Nasdaq: TAOX) and Petros Pharmaceutical, Inc. (OTC: PTPI). He previously served as a director of Protagenic Therapeutics, Inc. (Nasdaq: PTIX) from 2016 to 2022. Mr. Silverman received his B.A. from Lehigh University in 1992.
- Charles Larsen
-
Charles Larsen自2015年10月14日起担任董事会成员。Larsen先生在医疗器械行业拥有超过35年的运营和技术经验。他于1992年共同创立Novoste Corporation，并于1999年共同创立The Innovation Factory，通过他在The Innovation Factory的角色，他共同创立了其他公司，包括医疗设备公司，例如AcuFocus，Inc.，Aquesys Inc.，Halscion，Inc.，Neuronetics，Inc.和Sebacia，Inc.。他拥有超过30项已发布的美国和国际医疗设备专利。在加入Novoste之前，Larsen先生曾在Novoste Puerto Rico，Cordis Corporation，Key Pharmaceuticals和Parke-Davis/Warner Lambert担任执行，高级工程和项目管理职务。Larsen先生还担任AcuFocus，CardioFocus，Intuity Medical Inc.和Torax Medical，Inc.的董事会成员，这两家公司均为专业医疗或医疗器械公司。Larsen先生毕业于新泽西州理工学院，获得机械工程学士学位。
Charles Larsen,has over 35 years of operating and technical experience in the medical device industry. He co-founded Novoste Corporation in 1992 and The Innovation Factory in 1999 and through his role at The Innovation Factory, he co-founded additional companies, including medical device companies such as Acufocus, Inc., AqueSys Inc., Halscion, Inc., Neuronetics, Inc. and Sebacia, Inc. He holds over 30 issued U.S. and international patents on medical devices. Before joining Novoste, Mr. Larsen held positions with Novoste Puerto Rico, Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Mr. Larsen also serves on the Board of Directors of Acufocus, CardioFocus, Intuity Medical Inc., and Torax Medical, Inc, each specialty medical or medical device companies. Mr. Larsen is a graduate of the New Jersey Institute of Technology with a B.S. in Mechanical Engineering. - Charles Larsen自2015年10月14日起担任董事会成员。Larsen先生在医疗器械行业拥有超过35年的运营和技术经验。他于1992年共同创立Novoste Corporation，并于1999年共同创立The Innovation Factory，通过他在The Innovation Factory的角色，他共同创立了其他公司，包括医疗设备公司，例如AcuFocus，Inc.，Aquesys Inc.，Halscion，Inc.，Neuronetics，Inc.和Sebacia，Inc.。他拥有超过30项已发布的美国和国际医疗设备专利。在加入Novoste之前，Larsen先生曾在Novoste Puerto Rico，Cordis Corporation，Key Pharmaceuticals和Parke-Davis/Warner Lambert担任执行，高级工程和项目管理职务。Larsen先生还担任AcuFocus，CardioFocus，Intuity Medical Inc.和Torax Medical，Inc.的董事会成员，这两家公司均为专业医疗或医疗器械公司。Larsen先生毕业于新泽西州理工学院，获得机械工程学士学位。
- Charles Larsen,has over 35 years of operating and technical experience in the medical device industry. He co-founded Novoste Corporation in 1992 and The Innovation Factory in 1999 and through his role at The Innovation Factory, he co-founded additional companies, including medical device companies such as Acufocus, Inc., AqueSys Inc., Halscion, Inc., Neuronetics, Inc. and Sebacia, Inc. He holds over 30 issued U.S. and international patents on medical devices. Before joining Novoste, Mr. Larsen held positions with Novoste Puerto Rico, Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Mr. Larsen also serves on the Board of Directors of Acufocus, CardioFocus, Intuity Medical Inc., and Torax Medical, Inc, each specialty medical or medical device companies. Mr. Larsen is a graduate of the New Jersey Institute of Technology with a B.S. in Mechanical Engineering.
- Edward Uzialko
-
Edward Uzialko自2005年8月以来一直担任我们的董事会成员。Uzialko先生从1991年开始担任Lynk Systems，Inc.的创始人兼首席执行官，直到2004年被苏格兰皇家银行收购为止。Lynk提供电子支付，现金分配和电子商务服务。Lynk是一家提供全方位服务的增值经销商，为惠普、摩托罗拉、微软和其他各种技术产品提供硬件、软件和项目开发方面的持续支持。自2007年以来，Uzialko先生还一直担任信用卡处理公司Mainstream Merchant Services的所有者兼首席执行官。Uzialko先生于1969年至1973年在佛罗里达理工学院学习。
Edward Uzialko,was the founder and Chief Executive Officer of Lynk Systems, Inc. from 1991 until it was acquired by Royal Bank of Scotland in 2004. Lynk was a provider of merchant payment and ATM processing services to merchants. Mr. Uzialko has also served as the owner and Chief Executive Officer of Mainstream Merchant Services, a merchant processing company, from 2007 until it was acquired. Mr. Uzialko also held positions with First Financial Management Corporation and Intercept. - Edward Uzialko自2005年8月以来一直担任我们的董事会成员。Uzialko先生从1991年开始担任Lynk Systems，Inc.的创始人兼首席执行官，直到2004年被苏格兰皇家银行收购为止。Lynk提供电子支付，现金分配和电子商务服务。Lynk是一家提供全方位服务的增值经销商，为惠普、摩托罗拉、微软和其他各种技术产品提供硬件、软件和项目开发方面的持续支持。自2007年以来，Uzialko先生还一直担任信用卡处理公司Mainstream Merchant Services的所有者兼首席执行官。Uzialko先生于1969年至1973年在佛罗里达理工学院学习。
- Edward Uzialko,was the founder and Chief Executive Officer of Lynk Systems, Inc. from 1991 until it was acquired by Royal Bank of Scotland in 2004. Lynk was a provider of merchant payment and ATM processing services to merchants. Mr. Uzialko has also served as the owner and Chief Executive Officer of Mainstream Merchant Services, a merchant processing company, from 2007 until it was acquired. Mr. Uzialko also held positions with First Financial Management Corporation and Intercept.
- Kathy Lee Sepsick
-
自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
Kathy Lee Sepsick,has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 200 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry. - 自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
- Kathy Lee Sepsick,has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 200 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry.
- Alistair Milnes
-
Alistair Milnes，自2022年1月起在临床阶段的生物制药公司Bicycle治疗担任首席运营官，此前曾于2021年1月至2021年12月担任人力资源和传播副总裁。此前，他曾于2020年1月至2020年12月在力拓担任战略顾问，专注于转型、人员和沟通，并于2010年至2019年10月在Gazprom Marketing & Trading Ltd.担任职责不断增加的角色，包括于2017年12月至2019年10月担任全球人力资源和传播总监，并于2013年至2017年11月担任全球人力资源总监。Milnes先生获得了爱丁堡内皮尔大学的学士学位。
Alistair Milnes,has served as Chief Operating Officer at Bicycle Therapeutics, a clinical-stage biopharmaceutical company, since January 2022 and previously served as Vice President, Human Resources and Communications from January 2021 to December 2021. Previously, he served as Strategic Advisor at Rio Tinto with a focus on transformation, people and communications from January 2020 to December 2020, and in roles of increasing responsibility at Gazprom Marketing & Trading Ltd., from 2010 to October 2019, including serving as Director of Global Human Resources and Communications, from December 2017 to October 2019 and Director of Global Human Resources from 2013 to November 2017. Mr. Milnes received his B.A. from Edinburgh Napier University. - Alistair Milnes，自2022年1月起在临床阶段的生物制药公司Bicycle治疗担任首席运营官，此前曾于2021年1月至2021年12月担任人力资源和传播副总裁。此前，他曾于2020年1月至2020年12月在力拓担任战略顾问，专注于转型、人员和沟通，并于2010年至2019年10月在Gazprom Marketing & Trading Ltd.担任职责不断增加的角色，包括于2017年12月至2019年10月担任全球人力资源和传播总监，并于2013年至2017年11月担任全球人力资源总监。Milnes先生获得了爱丁堡内皮尔大学的学士学位。
- Alistair Milnes,has served as Chief Operating Officer at Bicycle Therapeutics, a clinical-stage biopharmaceutical company, since January 2022 and previously served as Vice President, Human Resources and Communications from January 2021 to December 2021. Previously, he served as Strategic Advisor at Rio Tinto with a focus on transformation, people and communications from January 2020 to December 2020, and in roles of increasing responsibility at Gazprom Marketing & Trading Ltd., from 2010 to October 2019, including serving as Director of Global Human Resources and Communications, from December 2017 to October 2019 and Director of Global Human Resources from 2013 to November 2017. Mr. Milnes received his B.A. from Edinburgh Napier University.
- Joshua Silverman
-
Joshua Silverman，自2022年起担任PharmaCyte Biotech临时首席执行官、临时总裁、临时董事长兼董事。他是Parkfield Funding LLC的联合创始人和管理成员，并且是Iroquois Capital Management，LLC的前首席和管理合伙人。此前，他曾于2003年至2016年担任Iroquois的联席首席投资官，并于2000年至2003年担任Vertical Ventures，LLC的联席首席投资官。西尔弗曼先生曾担任美国总统助理新闻秘书。Silverman先生还在Ayro Inc.、TNF Pharmaceuticals，Inc.、Petros Pharmaceuticals，Inc.和Synaptogenix, Inc.的董事会任职。Silverman先生获得了利哈伊大学的学士学位。
Joshua Silverman,has served as the interim Chief Executive Officer, interim President, interim Chairman and Director of PharmaCyte Biotech since 2022. He is the Co-Founder and Managing Member of Parkfield Funding LLC and is a former Principal and Managing Partner of Iroquois Capital Management, LLC. Previously, he served as Co-Chief Investment Officer of Iroquois from 2003 until 2016 and Co-Chief Investment Officer of Vertical Ventures, LLC from 2000 to 2003. Mr. Silverman served as Assistant Press Secretary to The President of The United States. Mr. Silverman also serves on the boards of directors of Ayro Inc., TNF Pharmaceuticals, Inc., Petros Pharmaceuticals, Inc. and Synaptogenix, Inc. Mr. Silverman received his B.A. from Lehigh University. - Joshua Silverman，自2022年起担任PharmaCyte Biotech临时首席执行官、临时总裁、临时董事长兼董事。他是Parkfield Funding LLC的联合创始人和管理成员，并且是Iroquois Capital Management，LLC的前首席和管理合伙人。此前，他曾于2003年至2016年担任Iroquois的联席首席投资官，并于2000年至2003年担任Vertical Ventures，LLC的联席首席投资官。西尔弗曼先生曾担任美国总统助理新闻秘书。Silverman先生还在Ayro Inc.、TNF Pharmaceuticals，Inc.、Petros Pharmaceuticals，Inc.和Synaptogenix, Inc.的董事会任职。Silverman先生获得了利哈伊大学的学士学位。
- Joshua Silverman,has served as the interim Chief Executive Officer, interim President, interim Chairman and Director of PharmaCyte Biotech since 2022. He is the Co-Founder and Managing Member of Parkfield Funding LLC and is a former Principal and Managing Partner of Iroquois Capital Management, LLC. Previously, he served as Co-Chief Investment Officer of Iroquois from 2003 until 2016 and Co-Chief Investment Officer of Vertical Ventures, LLC from 2000 to 2003. Mr. Silverman served as Assistant Press Secretary to The President of The United States. Mr. Silverman also serves on the boards of directors of Ayro Inc., TNF Pharmaceuticals, Inc., Petros Pharmaceuticals, Inc. and Synaptogenix, Inc. Mr. Silverman received his B.A. from Lehigh University.
高管简历
中英对照 | 中文 | 英文- Kathy Lee Sepsick
自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
Kathy Lee Sepsick,has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 200 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry.- 自2004年2月以来，我们的创始人Kathy Lee Sepsick一直担任我们的首席执行官兼总裁兼董事会主席。Lee-Sepsick女士在医疗技术行业担任了近三十年的高级管理人员，在成长中的新兴公司和公司运营部门积累了成功的记录。她在全球拥有超过100项Femasys产品和候选产品的专利。Lee-Sepsick女士在初创企业Novoste Corporation（血管内治疗解决方案的开发商）和Salumedica（人工软骨的生物材料开发商）的产品和公司生命周期的各个阶段发挥了重要作用，并承担了国家，运营和执行职责。职业生涯之初，她曾担任Terumo Medical Corporation的产品管理职务，在那里她曾担任波士顿科学国际有限公司的战略合作伙伴的管理职务。Lee-Sepsick女士还担任Georgia Bio的董事会成员。Lee-Sepsick女士毕业于罗格斯大学，拥有MBA和学士学位。在生物化学中。
- Kathy Lee Sepsick,has served as a senior executive in the medical technologies industry for nearly three decades, compiling a successful track record in growing emerging companies and corporate operating divisions. She holds over 200 patents globally for Femasys products and product candidates. Ms. Lee-Sepsick was instrumental in the various stages of product and company life cycles with strategic, operational, and executive responsibilities, at start-ups Novoste Corporation, developer of intravascular therapy solution and SaluMedica, biomaterial developer of artificial cartilage. At the onset of her career, Ms. Lee-Sepsick served in a product management role at Terumo Medical Corporation, where she was integral in the management of strategic partner, Boston Scientific Corporation. Ms. Lee-Sepsick is a graduate of Rutgers University with an MBA and a BS in Biochemistry.
- Christine Thomas
Christine Thomas，自2022年10月起担任Femasys Inc.监管和临床事务高级副总裁。Thomas女士在监管和临床事务方面拥有20多年的成功领导经验，包括全球战略制定、运营和医疗设备公司的执行责任，如GE医疗、波士顿科学、Smiths Medical和RTI Surgical，以及为大型临床研究机构艾昆纬提供专注于FDA的顾问专业知识。在她的职业生涯中，托马斯女士曾担任过监管、质量、设计保证、临床和合规方面的副总裁。托马斯女士在多个并购机会中担任过监管、临床和质量方面的主管，这些机会既包括剥离产品线，也包括收购多家公司。托马斯拥有威斯康星大学怀特沃特分校的教育学士学位，目前在约翰霍普金斯大学攻读理学硕士课程。
Christine Thomas,has over 20 years of successful leadership in regulatory and clinical affairs, including global strategy development, operations, and executive responsibility for medical device companies, such as GE Healthcare, Boston Scientific, Smiths Medical, and RTI Surgical, as well as providing FDA focused consultant expertise with IQVIA a large clinical research organization. Ms. Thomas has served as vice president of regulatory, quality, design assurance, clinical and compliance over her career. Ms. Thomas has been the regulatory, clinical, and quality lead on multiple M&A opportunities for both divestiture of product lines and acquisitions for several companies. Ms. Thomas holds a BS in Education from University of Wisconsin – Whitewater and is currently in the Johns Hopkins Master of Science program.- Christine Thomas，自2022年10月起担任Femasys Inc.监管和临床事务高级副总裁。Thomas女士在监管和临床事务方面拥有20多年的成功领导经验，包括全球战略制定、运营和医疗设备公司的执行责任，如GE医疗、波士顿科学、Smiths Medical和RTI Surgical，以及为大型临床研究机构艾昆纬提供专注于FDA的顾问专业知识。在她的职业生涯中，托马斯女士曾担任过监管、质量、设计保证、临床和合规方面的副总裁。托马斯女士在多个并购机会中担任过监管、临床和质量方面的主管，这些机会既包括剥离产品线，也包括收购多家公司。托马斯拥有威斯康星大学怀特沃特分校的教育学士学位，目前在约翰霍普金斯大学攻读理学硕士课程。
- Christine Thomas,has over 20 years of successful leadership in regulatory and clinical affairs, including global strategy development, operations, and executive responsibility for medical device companies, such as GE Healthcare, Boston Scientific, Smiths Medical, and RTI Surgical, as well as providing FDA focused consultant expertise with IQVIA a large clinical research organization. Ms. Thomas has served as vice president of regulatory, quality, design assurance, clinical and compliance over her career. Ms. Thomas has been the regulatory, clinical, and quality lead on multiple M&A opportunities for both divestiture of product lines and acquisitions for several companies. Ms. Thomas holds a BS in Education from University of Wisconsin – Whitewater and is currently in the Johns Hopkins Master of Science program.
- Dov Elefant
Dov Elefant，2019年9月被任命为Celletar Biosciences，Inc.副总裁兼首席财务官。最近，他于2015年9月至2019年8月担任Akari Therapeutics PLC的首席财务官，这是一家专门治疗自身免疫性和炎症性疾病的上市生物制药公司。在Akari Therapeutics，PLC任职之前，Elefant先生于2012年1月至2015年9月担任Celsus Therapeunics，Inc.（一家公开上市的生物制药公司）的首席财务官。他持有Yeshiva University的会计学士学位。
Dov Elefant,served as the vice president and CFO of Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer drugs, from September 2019 to February 2022. He served as Chief Financial Officer at Akari Therapeutics, Plc from January 2012 to September 2019. Prior to his role at Akari Therapeutics, Plc, he was Chief Financial Officer at Althera Medical Ltd. Mr. Elefant holds a B.S. in Accounting from the Sy Syms School of Business at Yeshiva University.- Dov Elefant，2019年9月被任命为Celletar Biosciences，Inc.副总裁兼首席财务官。最近，他于2015年9月至2019年8月担任Akari Therapeutics PLC的首席财务官，这是一家专门治疗自身免疫性和炎症性疾病的上市生物制药公司。在Akari Therapeutics，PLC任职之前，Elefant先生于2012年1月至2015年9月担任Celsus Therapeunics，Inc.（一家公开上市的生物制药公司）的首席财务官。他持有Yeshiva University的会计学士学位。
- Dov Elefant,served as the vice president and CFO of Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer drugs, from September 2019 to February 2022. He served as Chief Financial Officer at Akari Therapeutics, Plc from January 2012 to September 2019. Prior to his role at Akari Therapeutics, Plc, he was Chief Financial Officer at Althera Medical Ltd. Mr. Elefant holds a B.S. in Accounting from the Sy Syms School of Business at Yeshiva University.